Details of the Drug

General Information of Drug (ID: DMHW289)

Drug Name

DCC-3014

Synonyms

Vimseltinib; UNII-PX9FTM69BF; PX9FTM69BF; DCC3014; 1628606-05-2; 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one; 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one; Vimseltinib [INN]; SCHEMBL16047448; GTPL11190; EX-A4700; NSC828316; NSC-828316; example 10 [WO2014145025A2]; HY-136256; CS-0121044; 3-Methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-4(3H)-pyrimidinone; 4(3H)-Pyrimidinone, 3-methyl-2-((1-methylethyl)amino)-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)-4-pyridinyl)oxy)-2-pyridinyl)-

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]
Haematological malignancy	2B33.Y	Phase 1	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

431.5

Logarithm of the Partition Coefficient (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

Chemical Identifiers

Formula: C23H25N7O2
IUPAC Name: 3-methyl-5-[6-methyl-5-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxypyridin-2-yl]-2-(propan-2-ylamino)pyrimidin-4-one
Canonical SMILES: CC1=C(C=CC(=N1)C2=CN=C(N(C2=O)C)NC(C)C)OC3=CC(=NC=C3)C4=CN(N=C4)C
InChI: InChI=1S/C23H25N7O2/c1-14(2)27-23-25-12-18(22(31)30(23)5)19-6-7-21(15(3)28-19)32-17-8-9-24-20(10-17)16-11-26-29(4)13-16/h6-14H,1-5H3,(H,25,27)
InChIKey: TVGAHWWPABTBCX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 86267612
CAS Number: 1628606-05-2
TTD ID: D9RH0V

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Macrophage colony-stimulating factor 1 receptor (CSF1R)	TT7MRDV	CSF1R_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT03069469) Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor. U.S. National Institutes of Health.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)